GO:0070061 fructose binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070061 fructose binding is a molecular_function term defined as binding to the D- or L-enantiomer of fructose, the ketohexose arabino-hex-2-ulose.
• Fructose binding is central to fructose transport, fructolysis, and fructose-sensing pathways in intestine, liver, adipose tissue, and immune cells.
• Key fructose-binding proteins include KHK-A/C, GLUT5 (SLC2A5), GLUT2 (SLC2A2), and ChREBP (MLXIPL), each with distinct binding pockets and regulatory roles.
• Residues in the fructose-binding pocket of ketohexokinase-A are required for catalytic activity, making the pocket a target for functional studies.
• Fructose binding and metabolism are linked to metabolic dysfunction-associated steatotic liver disease, hepatocellular carcinogenesis, and Th17 cell pathogenicity.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of fructose-binding proteins in disease and metabolism.
Description
Fructose binding (GO:0070061) is a molecular_function term that describes the selective interaction of a protein or biomolecule with the D- or L-enantiomer of fructose, a ketohexose also known as arabino-hex-2-ulose. This binding event is the first committed step in fructose sensing, transport, and metabolism, and it underlies diverse physiological processes ranging from intestinal absorption to hepatic lipogenesis and immune cell activation. Because fructose is a dietary sugar increasingly implicated in metabolic disease, understanding the proteins that bind it is a high-priority research area. At the molecular level, fructose binding is mediated by defined pockets in transporters, kinases, and transcription factor complexes. For example, the fructose-binding pocket of ketohexokinase-A (KHK-A) contains residues that are required for enzymatic activity, and mutation of these residues alters fructose phosphorylation. Similarly, the facilitative transporter GLUT5 (SLC2A5) and the glucose/fructose transporter GLUT2 (SLC2A2) bind fructose to mediate uptake across the apical and basolateral membranes of enterocytes. In the nucleus, the carbohydrate response element-binding protein (ChREBP, encoded by MLXIPL) responds to fructose-derived metabolites to regulate gene expression. For researchers, GO:0070061 provides a precise annotation for experiments that measure fructose-protein interactions, including binding assays, structural studies, and functional genomics. The term is also relevant to disease models, as fructose binding and downstream metabolism have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD), hepatocellular carcinogenesis, and Th17-mediated inflammation. This article reviews the definition, mechanism, key genes, disease links, and CRISPR-based research methods for fructose binding.
fructose binding At A Glance
| GO ID | GO:0070061 |
|---|---|
| GO term | fructose binding |
| Ontology | molecular_function |
| Synonym | (none) |
| Definition | Binding to the D- or L-enantiomer of fructose, the ketohexose arabino-hex-2-ulose. |
| Major function | Selective recognition and non-covalent interaction with fructose, enabling transport, phosphorylation, or sensing. |
| Related processes | Fructose transport, fructolysis, lipogenesis, and carbohydrate-responsive gene regulation. |
| Example proteins | KHK-A/C, GLUT5 (SLC2A5), GLUT2 (SLC2A2), ChREBP (MLXIPL). |
| Disease relevance | MASLD, hepatocellular carcinogenesis, Th17-mediated inflammation. |
What Is GO:0070061?
GO:0070061 fructose binding is defined by the Gene Ontology as the binding to the D- or L-enantiomer of fructose, the ketohexose arabino-hex-2-ulose. In practical terms, it describes any molecular interaction in which a protein, nucleic acid, or small molecule selectively recognizes and non-covalently associates with fructose. This binding can be transient, as in substrate recognition by a kinase, or stable, as in a transporter-ligand complex. The term is a child of carbohydrate binding and is distinct from fructose transport or fructose metabolic process, although these functions are often coupled in vivo.
Why Is fructose binding Important in Cell Biology?
Fructose binding is important because it gates the entry of fructose into cellular metabolism and signaling. Unlike glucose, fructose is metabolized largely independently of phosphofructokinase regulation, so the rate of fructose binding and subsequent phosphorylation can drive lipogenesis and metabolic stress. Dysregulated fructose binding and metabolism have been linked to metabolic dysfunction-associated steatotic liver disease, hepatocellular carcinogenesis, and immune cell pathogenicity, making this term a focal point for therapeutic and diagnostic research. Understanding which proteins bind fructose, where, and with what affinity is therefore essential for both basic biology and translational medicine.
• Fructose binding initiates intestinal fructose absorption via GLUT5 and GLUT2, a process reviewed in detail by Ferraris et al..
• Hepatic fructose binding and metabolism contribute to de novo lipogenesis and MASLD pathogenesis.
• Ketohexokinase-A fructose-binding pocket residues are required for activity, linking binding to catalytic function.
• ChREBP (MLXIPL) senses fructose-derived metabolites to regulate glycolytic and lipogenic genes.
• Fructose uptake by brown adipose tissue is independent of ChREBP and does not cause elevated de novo lipogenesis, highlighting tissue-specific binding roles.
• Fructose intake can promote Th17 cell generation and pathogenicity through a glycolysis-ROS-EGFR axis.
• Fructose 1-phosphate, a product of fructose binding and phosphorylation, inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis.
• Selenium binding protein 1 (SBP1) suppresses fructose-induced metabolic dysfunction-associated steatotic liver disease.
• Fructose supplementation has been studied for effects on serum sex hormone-binding globulin and testosterone levels.
• CRISPR models enable causal testing of fructose-binding proteins in metabolic and immune diseases.
Molecular Mechanism of fructose binding
Substrate recognition and binding pocket architecture
In simple terms: Proteins that bind fructose have a pocket shaped to hold the sugar.
Fructose binding occurs in a specialized pocket formed by hydrogen-bonding and hydrophobic residues. In ketohexokinase-A (KHK-A), residues in the fructose-binding pocket are required for activity, and mutations in these residues reduce fructose phosphorylation. Transporters such as GLUT5 (SLC2A5) and GLUT2 (SLC2A2) also contain stereoselective pockets that recognize fructose for facilitated diffusion across membranes. The specificity for D- or L-fructose depends on the arrangement of these residues and the conformational state of the protein.
Fructose transport and cellular uptake
In simple terms: Fructose must be carried into cells by transporter proteins.
Intestinal absorption of fructose is mediated by GLUT5 on the apical membrane and GLUT2 on the basolateral membrane, as reviewed by Ferraris et al.. These transporters bind fructose with distinct affinities and are regulated by dietary and hormonal signals. In brown adipose tissue, fructose uptake is independent of carbohydrate response element-binding protein (ChREBP) and does not cause elevated de novo lipogenesis, indicating tissue-specific transport and binding mechanisms.
Fructose phosphorylation and metabolic commitment
In simple terms: After binding, fructose is often phosphorylated to trap it in the cell.
Ketohexokinase (KHK) binds fructose and catalyzes its phosphorylation to fructose 1-phosphate. The fructose-binding pocket residues of KHK-A are essential for this activity. Fructose 1-phosphate can then be cleaved by aldolase B into dihydroxyacetone phosphate and glyceraldehyde, entering glycolysis and lipogenesis. This phosphorylation step is a key commitment point that distinguishes fructose from glucose metabolism.
Transcriptional sensing via ChREBP
In simple terms: Some proteins bind fructose-derived molecules to switch genes on or off.
The carbohydrate response element-binding protein (ChREBP, gene MLXIPL) is a transcription factor that responds to fructose-derived metabolites, including fructose 1-phosphate and xylulose 5-phosphate, to regulate glycolytic and lipogenic gene expression. Iizuka reviewed the role of ChREBP in intestinal and hepatic fructose metabolism, showing that ChREBP activity is modulated by fructose availability and binding of metabolite ligands. This creates a feedback loop between fructose binding, metabolism, and gene regulation.
Fructose binding in immune and endocrine contexts
In simple terms: Fructose binding also affects immune cells and hormone levels.
Fructose intake driven by glycolysis-ROS-EGFR signaling specifically promotes the generation and pathogenicity of Th17 cells, indicating that fructose binding and metabolism in immune cells can shape inflammatory responses. In a randomized controlled trial post-hoc analysis, glucose and fructose supplementation affected serum sex hormone-binding globulin and testosterone levels, suggesting endocrine effects of fructose exposure. These findings expand the physiological relevance of fructose binding beyond classical metabolic tissues.
Key Genes Involved in GO:0070061 fructose binding
The following genes and proteins are directly implicated in fructose binding, transport, sensing, or downstream metabolism based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KHK | Fructose phosphorylation; fructose-binding pocket required for activity | Target for metabolic liver disease and HCC studies |
| SLC2A5 (GLUT5) | Apical fructose transporter in intestine | Intestinal fructose absorption research |
| SLC2A2 (GLUT2) | Basolateral fructose and glucose transporter | Enterocyte and hepatocyte fructose uptake |
| MLXIPL (ChREBP) | Transcription factor sensing fructose metabolites | Fructose-driven lipogenesis and gene regulation |
| SBP1 (SELENBP1) | Suppresses fructose-induced MASLD | Protective role in steatotic liver disease |
| MPI | Mannose phosphate isomerase inhibited by fructose 1-phosphate | Hepatocellular carcinogenesis suppression |
| EGFR | Signaling node in fructose-driven Th17 pathogenicity | Immune cell metabolism and inflammation |
| ALDOB | Aldolase B cleaves fructose 1-phosphate | Hereditary fructose intolerance and fructolysis |
| GCK | Glucokinase phosphorylates glucose; indirect fructose metabolism | Hepatic sugar sensing |
| PKLR | Pyruvate kinase in glycolysis downstream of fructose | Metabolic flux studies |
| FASN | Fatty acid synthase in de novo lipogenesis | Fructose-induced lipogenesis |
| ACACA | Acetyl-CoA carboxylase in lipogenesis | Fructose-driven MASLD models |
| TXN | Thioredoxin in ROS balance | Fructose-induced oxidative stress |
| IL17A | Th17 effector cytokine | Fructose-driven autoimmunity models |
| SHBG | Sex hormone-binding globulin | Endocrine effects of fructose supplementation |
| UCP1 | Brown adipose tissue thermogenesis | Fructose uptake in BAT |
| SLC2A1 (GLUT1) | Basal glucose/fructose transport in some tissues | Comparative fructose transport studies |
How Is fructose binding Regulated?
Fructose binding and downstream metabolism are regulated at multiple levels. Dietary fructose availability influences the expression and membrane localization of GLUT5 and GLUT2 in the intestine. ChREBP (MLXIPL) integrates fructose-derived metabolite signals to transcriptionally regulate glycolytic and lipogenic enzymes, creating a feed-forward loop. In brown adipose tissue, fructose uptake is independent of ChREBP, indicating alternative regulatory mechanisms. KHK activity is controlled by the integrity of its fructose-binding pocket, and mutations in these residues alter flux. Additionally, fructose 1-phosphate can inhibit mannose phosphate isomerase, linking fructose binding to broader metabolic regulation.
fructose binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SBP1 (SELENBP1) | MASLD suppression | Knockout and overexpression in hepatocytes |
| MPI | Hepatocellular carcinogenesis | Point mutation and knockout in liver cancer cells |
| KHK | Fructose metabolism and liver disease | Fructose-binding pocket point mutants |
| EGFR | Th17-mediated inflammation | Knockout in T cells and Th17 differentiation assays |
| SHBG | Endocrine effects of fructose | Overexpression and knock-in models |
Fructose binding in metabolic dysfunction-associated steatotic liver disease (MASLD)
Fructose binding and metabolism contribute to hepatic steatosis and MASLD. Selenium binding protein 1 (SBP1) suppresses fructose-induced metabolic dysfunction-associated steatotic liver disease, indicating a protective role against fructose-driven liver injury. ChREBP-mediated sensing of fructose metabolites promotes lipogenic gene expression, which can exacerbate fat accumulation in the liver. These findings position fructose-binding proteins as potential therapeutic targets in MASLD.
Fructose binding and hepatocellular carcinogenesis
Fructose 1-phosphate, generated after fructose binding and phosphorylation by KHK, inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis. This suggests that fructose-binding and fructolytic flux can have tumor-suppressive effects in the liver, depending on context. KHK-A fructose-binding pocket residues are required for activity, linking binding directly to metabolic outcomes relevant to cancer.
Fructose binding in immune cell pathogenicity
Fructose intake driven by a glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells. This indicates that fructose binding and metabolism in immune cells can modulate inflammatory and autoimmune responses. The study highlights a mechanistic link between dietary fructose, cellular redox state, and T cell differentiation.
Endocrine and metabolic effects of fructose exposure
A post-hoc analysis of a double-blind randomized controlled trial showed that glucose and fructose supplementation affected serum sex hormone-binding globulin and testosterone levels. This suggests that fructose binding and metabolism may influence endocrine parameters, although the mechanisms require further study. Brown adipose tissue fructose uptake is independent of ChREBP and does not cause elevated de novo lipogenesis, indicating tissue-specific effects.
From fructose binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KHK fructose binding reduce fructolysis? | KHK knockout and point-mutation cell lines |
| Does SBP1 protect against fructose-induced MASLD? | SBP1 overexpression and knockout hepatocytes |
| Does fructose 1-phosphate inhibit MPI in liver cancer? | MPI point-mutation and knockout models |
| Does ChREBP mediate fructose sensing? | MLXIPL knockout and knock-in reporter lines |
| Does fructose uptake in BAT require ChREBP? | BAT-specific ChREBP knockout mice |
| Does fructose drive Th17 pathogenicity via EGFR? | EGFR knockout T cells and Th17 assays |
How to Study the fructose binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Fructose-protein interaction studies |
| Surface plasmon resonance | Real-time binding kinetics | Transporter-ligand affinity |
| X-ray crystallography / cryo-EM | Three-dimensional binding pocket structure | Residue-level mechanism |
| Isotope tracing | Fructose uptake and metabolic flux | Intestinal and hepatic metabolism |
| RNA-seq | Transcriptional responses to fructose | ChREBP target gene discovery |
| ChIP-seq | ChREBP DNA binding sites | Fructose-responsive enhancer mapping |
| CRISPR knockout screens | Genes required for fructose phenotypes | Functional genomics of fructose binding |
| Th17 differentiation assays | Immune cell pathogenicity | Fructose-driven inflammation |
Binding assays and structural biology
Fructose binding can be measured using isothermal titration calorimetry, surface plasmon resonance, and fluorescence-based binding assays. Structural studies such as X-ray crystallography or cryo-EM can resolve the fructose-binding pocket, as demonstrated for KHK-A residues required for activity. These methods provide affinity and specificity data for D- and L-fructose.
Metabolic flux and isotope tracing
Isotope-labeled fructose can be used to trace uptake and metabolism in cells and tissues. This approach has been used to study intestinal fructose absorption and hepatic fructolysis. Flux analysis can distinguish binding-dependent transport from downstream metabolic conversion.
Transcriptomics and ChREBP target analysis
RNA-seq and ChIP-seq can identify genes regulated by ChREBP in response to fructose availability. These methods help define the transcriptional network downstream of fructose binding and sensing. Comparative studies in knockout and wild-type cells reveal direct targets.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for fructose binding, uptake, or toxicity. Such screens are complemented by targeted point-mutation and knock-in models to test specific residues in fructose-binding pockets. These approaches enable causal inference in metabolic and immune disease models.
How CRISPR Can Be Used to Study GO:0070061 fructose binding
Knockout
CRISPR knockout of genes encoding fructose-binding proteins such as KHK, SLC2A5, SLC2A2, or MLXIPL can abolish fructose uptake or sensing. Knockout models have been used to demonstrate the role of SBP1 in suppressing fructose-induced MASLD and the role of MPI in hepatocellular carcinogenesis. These models provide causal evidence for gene function in fructose binding pathways.
Point Mutation
Point mutations in fructose-binding pocket residues, such as those in KHK-A, can selectively disrupt binding without eliminating protein expression. This approach is ideal for dissecting binding affinity from catalytic activity and for validating structural predictions. Point-mutation models are also useful for studying disease-associated variants.
Knock-in
Knock-in of tagged or reporter alleles allows visualization and quantification of fructose-binding proteins in live cells. For example, fluorescent tagging of GLUT5 or ChREBP enables tracking of localization and dynamics. Knock-in models can also introduce human disease variants into model organisms.
Overexpression
Overexpression of fructose-binding proteins such as SBP1 or ChREBP can test gain-of-function effects in metabolic and inflammatory contexts. Overexpression models are valuable for identifying protective or pathogenic roles of fructose binding in disease.
How EDITGENE Supports fructose binding Research
Researchers studying fructose binding-related genes often need to determine whether a candidate gene is causally involved in fructose uptake, sensing, or downstream metabolism. EDITGENE provides CRISPR-based cell models and screening services to enable these causal experiments with high specificity and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for fructose binding research.
Frequently Asked Questions About fructose binding
What is fructose binding (GO:0070061)?
Fructose binding is a molecular_function term defined as binding to the D- or L-enantiomer of fructose, the ketohexose arabino-hex-2-ulose.
What genes are involved in fructose binding?
Key genes include KHK, SLC2A5 (GLUT5), SLC2A2 (GLUT2), MLXIPL (ChREBP), SBP1, and MPI, among others.
How does fructose binding relate to liver disease?
Fructose binding and metabolism contribute to MASLD and hepatocellular carcinogenesis, with SBP1 and MPI playing protective roles.
What is the fructose-binding pocket in ketohexokinase-A?
The fructose-binding pocket of KHK-A contains residues required for activity, and mutations in these residues reduce fructose phosphorylation.
Does fructose binding affect immune cells?
Yes, fructose intake driven by a glycolysis-ROS-EGFR axis promotes Th17 cell generation and pathogenicity.
Is fructose uptake in brown adipose tissue dependent on ChREBP?
No, fructose uptake by brown adipose tissue is independent of ChREBP and does not cause elevated de novo lipogenesis.
What methods are used to study fructose binding?
Methods include isothermal titration calorimetry, surface plasmon resonance, crystallography, isotope tracing, RNA-seq, and CRISPR screens.
How can CRISPR help study fructose binding?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of fructose-binding proteins in disease.
What is the role of ChREBP in fructose metabolism?
ChREBP senses fructose-derived metabolites to regulate glycolytic and lipogenic gene expression.
Does fructose supplementation affect hormone levels?
A post-hoc analysis of a randomized controlled trial showed effects on serum sex hormone-binding globulin and testosterone levels.
Conclusion
Fructose binding (GO:0070061) is a fundamental molecular function that governs fructose transport, phosphorylation, and sensing across tissues. Its dysregulation is linked to MASLD, hepatocellular carcinogenesis, and Th17-mediated inflammation, making it a compelling target for metabolic and immune research. CRISPR-based models provide powerful tools to dissect the causal roles of fructose-binding proteins and to identify new therapeutic opportunities.
References
- 1. Koga T et al.. 2025. Selenium binding protein 1 (SBP1) suppresses fructose-induced metabolic dysfunction-associated steatotic liver disease.. Biochem Biophys Res Commun 770:152013 PMID: 40381238
- 2. Wang Y et al.. 2026. Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis.. Signal Transduct Target Ther 11(1) PMID: 42178306
- 3. Iizuka K. 2017. The Role of Carbohydrate Response Element Binding Protein in Intestinal and Hepatic Fructose Metabolism.. Nutrients 9(2) PMID: 28241431
- 4. Ferreira JC et al.. 2024. Residues in the fructose-binding pocket are required for ketohexokinase-A activity.. J Biol Chem 300(8):107538 PMID: 38971308
- 5. Ferraris RP et al.. 2018. Intestinal Absorption of Fructose.. Annu Rev Nutr 38:41-67 PMID: 29751733
- 6. Chen H et al.. 2025. Effects of glucose and fructose supplementation on serum sex hormone-binding globulin and testosterone levels: Post-hoc analysis of a double-blind randomized controlled trial.. Clin Nutr ESPEN 69:384-388 PMID: 40721209
- 7. Liu X et al.. 2025. Fructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells.. Nat Commun 16(1):11115 PMID: 41276507
- 8. Behrens J et al.. 2025. Fructose uptake by brown adipose tissue is independent of carbohydrate response element-binding protein and does not cause elevated de novo lipogenesis.. Acta Biochim Biophys Sin (Shanghai) 58(7):1653-1666 PMID: 41408829
